Giotrif Extends Overall Survival in Japanese NSCLC Patients with Del19 EGFR Mutation: NBI

Nippon Boehringer Ingelheim’s (NBI) anticancer drug Giotrif (afatinib) significantly improved the overall survival (OS) of Japanese non-small cell lung cancer (NSCLC) patients with the Del19 EGFR mutation, according to the results of a subgroup analysis of Japanese patients enrolled in...read more